Company news
Gan & Lee Pharmaceuticals Co., Ltd. Class A (SSE:603087) news
Gan & Lee Pharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Oct 25, 2025: Announcement on Convening the Q3 2025 Performance Briefing
Press releases — page 2
Announcement on Convening the Q3 2025 Performance Briefing
October 24, 2025
Announcement on the Implementation of Repurchase and Cancellation of Partial Restricted Shares in the 2022 and 2024 Restricted Stock Incentive Plans
September 26, 2025
Announcement on the Major Contract
September 23, 2025
Announcement on Canceling Repurchased Shares and Decreasing Registered Capital and Notification to Creditors
September 7, 2025
Announcement on Results of Shareholding Reduction by Senior Management Members
August 20, 2025
Announcement on the Result of Shareholding Reduction by Shareholder and Director
August 15, 2025
Announcement on Completion of Administration of the First Subject in Phase II Clinical Trial of GZR102 Injection
August 8, 2025
Announcement on Resolutions of the 3rd Meeting of the 5th Board of Supervisors
August 7, 2025
Announcement on Progress in Repurchasing Shares through Call Auction
August 1, 2025
Indicative Announcement on Changes in Shareholder's Equity
July 29, 2025
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
July 21, 2025
Announcement on Progress in Using Idle Raised Funds for Cash Management
July 14, 2025
Announcement on Redemption at Maturity of Idle Raised Funds Used for Cash Management
July 10, 2025
Announcement on Expected Increase in Semi-annual Performance for 2025
July 9, 2025
Announcement on Shareholding Reduction Plan of Shareholders, Directors and Senior Management Members
July 4, 2025
Indicative Announcement on Unlocking of the 2nd Sales Restriction Lifting Period under the 2022 Restricted Stock Incentive Plan and Unlocking and Listing of the 1st Sales Restriction Lifting Period under the 2024 Restricted Stock Incentive Plan
July 1, 2025
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
June 21, 2025
Announcement on Release of Pledge of Some Shares of Controlling Shareholder and Actual Controller
June 17, 2025
Announcement on Changing Legal Representative and Obtaining Renewed Business License
June 12, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 4, 2025
Announcement on Planning to Change Registered Capital and Amend the Articles of Association
May 30, 2025
Announcement on Electing Employee Representative Supervisor
May 20, 2025
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
March 10, 2025
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
December 18, 2024
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
November 12, 2024
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
November 11, 2024
Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
October 15, 2024
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
September 14, 2024
Gan & Lee Pharmaceuticals Bi-weekly twice a month GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
July 23, 2024
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
July 22, 2024
Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions
June 22, 2024
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions
June 16, 2024
Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18
March 10, 2022
Gan & Lee Pharmaceuticals : Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
October 14, 2021
Gan & Lee Pharmaceuticals : New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association's 81st Scientific Sessions
July 2, 2021